Phaseline

Targets › CAPN2

CAPN2 (Calpain-2 catalytic subunit): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Feb 2027.

Calcium-regulated non-lysosomal thiol-protease which catalyzes limited proteolysis of substrates involved in cytoskeletal remodeling and signal transduction. Proteolytically cleaves MYOC at 'Arg-226'. Proteolytically cleaves CPEB3 following neuronal stimulation which abolishes CPEB3 translational repressor activity, leading to translation of CPEB3 target mRNAs (By similarity). (UniProt, P17655)

Open in Phaseline: the race on CAPN2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Amylyx PharmaceuticalsAMX0114
Antisense oligonucleotide targeting calpain-2 mRNA
CAPN2Phase 1ALSFeb 2027

Conditions

ALS (1)

Modalities

small molecule (1)

Companies

Amylyx Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.